Heart failure Drug's biomarker effects scrutinized in japanese patients
NCT ID NCT07527767
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study used blood and urine samples from 236 Japanese patients with chronic heart failure to see how biomarkers like BNP change during treatment with sacubitril valsartan or enalapril. Researchers looked for links between biomarker changes and improvements in heart failure symptoms. The goal was to better understand how these drugs work in this specific population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacubitril valsartan
What this could lead to
If successful, this could help doctors better understand how sacubitril valsartan affects heart failure biomarkers, potentially improving treatment monitoring.
What could go wrong
This is a secondary analysis of existing data, not a new treatment trial. The findings may not lead to direct changes in patient care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE AND REDUCED EJECTION FRACTION (HFREF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative SIte
Tokyo, Tokyo, 105-6333, Japan